Quantcast

Latest Sanofi Stories

2014-07-09 16:28:51

Results from Earlier Clinical Trials Published Today in the New England Journal of Medicine TARRYTOWN, N.Y. and PARIS, July 9, 2014 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi (EURONEXT: SAN and NYSE: SNY) today announced positive results from a Phase 2b dose-ranging study of dupilumab, an investigational therapy, in adult patients with moderate-to-severe atopic dermatitis (AD), a serious, chronic form of eczema. All doses of dupilumab met the primary endpoint...

2014-07-08 08:31:22

- Toujeo dossier already accepted by EMA - PARIS, July 8, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the company's New Drug Application (NDA) for Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL), an investigational basal insulin. The acceptance of the NDA follows the acceptance of the marketing authorization dossier for Toujeo by the European Medicines Agency (EMA) for...

2014-07-03 12:26:08

STOCKHOLM, July 3, 2014 /PRNewswire/ -- Pharmalink AB, a specialty pharma company focused on orphan and niche products, is very pleased to announce that Mrs Ann-Tove Kongsnes, Mrs Hilde Furberg and Mr Olav Hellebo were elected as new members of its Board of Directors at the Company's recent shareholders' meeting held in Stockholm. At the same meeting, Ms Elisabeth Lindner stepped down from the Board. Ann-Tove Kongsnes (born 1967) is an Investment Director at Investinor,...

2014-07-01 16:29:58

ALBANY, N.Y., July 1, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that it has completed the acquisition of Oso Biopharmaceuticals Manufacturing, a former portfolio company of Altaris Capital Partners, LLC. The transaction is consistent with AMRI's strategy to be the preeminent supplier of custom and complex drug product development and manufacturing services to the pharmaceutical industry. OsoBio is recognized as a premier contract manufacturer of highly complex...

2014-07-01 08:31:10

- Triggered by ongoing and very successful multi-year collaboration TUBINGEN, Germany, July 1, 2014 /PRNewswire/ -- CureVac, a German clinical-stage biopharmaceutical company, today announced the execution of an exclusive license agreement with Sanofi Pasteur S.A., the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), to develop and commercialize an mRNA-based vaccine against an undisclosed pathogen. In 2011, CureVac and Sanofi Pasteur signed a collaboration and license...

2014-06-30 12:26:36

MONTREAL, June 30, 2014 /CNW Telbec/ - For more than 75 youngsters with life-threatening allergies, participating in a soccer clinic hosted by the Montreal Impact and Allerject(TM) was a dream come true. For an hour and a half on Sunday, June 29, the kids were put through their paces by the club's official Soccer Schools. "This event demonstrated to these young people that, with proper precaution and preparation - that they do not have to be defined by their allergies," says...

2014-06-23 08:28:43

ALBANY, N.Y., June 23, 2014 /PRNewswire/ -- AMRI (NASDAQ: AMRI) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended ("HSR"), in connection with AMRI's proposed acquisition of Oso Biopharmaceuticals Manufacturing, LLC ("OsoBio") was terminated by the United States Federal Trade Commission on June 20, 2014. As previously announced on June 2, 2014, AMRI entered into a definitive agreement to acquire all of the outstanding...

2014-06-14 12:21:08

PARIS, June 14, 2014 /PRNewswire/ -- Sanofi (EURONEXT: SAN and NYSE: SNY) announced today that Lyxumia(®) (lixisenatide) met the primary endpoint in an 8-week head-to-head pharmacodynamic study versus liraglutide, showing a significantly more pronounced post-prandial (after-meal) glucose (blood sugar) lowering effect after a test-meal than liraglutide when both were added to optimally titrated Lantus(®) (insulin glargine). Lowering of post-prandial glucose was measured as change...

2014-06-14 12:21:03

-- Real World Outcome Study of Patients with Type 2 Diabetes Presented at American Diabetes Association 74th Scientific Sessions -- BRIDGEWATER, N.J., June 14, 2014 /PRNewswire/ -- Sanofi US announced today results from a real world outcome study of type 2 diabetes (T2D) patients that show switching from Lantus® (insulin glargine [rDNA origin] injection) to insulin detemir demonstrated higher average blood sugar levels (A1C) and lower A1C reduction over a span of 12 months compared...

2014-06-13 08:24:31

SCRS Welcomes INC Research, inVentiv Health, Novartis and Sanofi ELLICOTT CITY, Md., June 13, 2014 /PRNewswire/ -- Leading sponsor and CRO organizations continue to join the Society for Clinical Research Sites' (SCRS) Global Impact Partner (GIP) program at a rapid pace. Since April 1, INC Research, inVentiv Health, Novartis and Sanofi have joined the SCRS GIP program. From its inception only one year ago, the initiative has quickly grown to 25 leading organizations. Global Impact...


Word of the Day
malpais
  • The ragged surface of a lava-flow.
'Malpais' translates from Spanish as 'bad land.'